Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359306 | 0.86 | ECE1 (0.44) | ECE1MAPTCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7359311 | 0.86 | ECE1 (0.44) | ECE1MAPTCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14456269 | 0.84 | ECE1 (0.39) | ECE1MAPTCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14200542 | 0.83 | MAPT (0.44) | MAPTCYP2D6CYP2C19ALDH1A1CA2 | |
| SCHEMBL7777341 | 0.82 | ECE1 (0.41) | ECE1MAPTALDH1A1ITGB2ICAM1 | |
| SCHEMBL9924205 | 0.79 | ECE1 (0.41) | ECE1ALDH1A1ITGB2ICAM1ITGAL | |
| SCHEMBL88481 | 0.79 | ECE1 (0.46) | ECE1ALDH1A1ITGB2ICAM1ITGAL | |
| SCHEMBL30406637 | 0.79 | ECE1 (0.46) | ECE1ALDH1A1ITGB2ICAM1ITGAL | |
| SCHEMBL88480 | 0.79 | ECE1 (0.46) | ECE1ALDH1A1ITGB2ICAM1ITGAL | |
| SCHEMBL7267077 | 0.78 | ECE1 (0.43) | ECE1ALDH1A1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ECE1 1266/4885MAPT 2759/4885CYP2D6 4660/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | ECE1 1266/4885MAPT 2759/4885CYP2D6 4660/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ECE1 1266/4885MAPT 2759/4885CYP2D6 4660/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | ECE1 3835/4885MAPT 4669/4885CYP2D6 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.